Who is sponsoring NCT03511820?

NCT03511820 is sponsored by TTY Biopharm.

What drugs are being tested in NCT03511820?

Interventions in NCT03511820: Lipo-AB® (amphotericin B) liposome.

What condition does NCT03511820 study?

NCT03511820 studies Neutropenia, Febrile.

Is NCT03511820 still recruiting?

NCT03511820 is currently completed. Last updated 30 April 2018.

Last reviewed 2018-04-30 · How we verify

NCT03511820

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever

Completed Last updated 30 April 2018

What this trial tests

trial testing Lipo-AB® (amphotericin B) liposome in Neutropenia, Febrile in 54 participants. Completed in 15 January 2018.

Timeline

24 May 2016

Primary endpoint
15 January 2018

15 January 2018

Quick facts

Lead sponsor	TTY Biopharm
Status	Completed
Study type	OBSERVATIONAL
Enrollment	54
Start date	24 May 2016
Primary completion	15 January 2018
Estimated completion	15 January 2018
Sites	9 locations across Taiwan

Drugs / interventions tested

Lipo-AB® (amphotericin B) liposome — full drug profile →

Conditions studied

Neutropenia, Febrile — all drugs for Neutropenia, Febrile →

Sponsor

TTY Biopharm — full company profile →

Who can join

Eligibility, any sex, with Neutropenia, Febrile. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Amphotericin B is a polyene antifungal drug used for the treatment of many systemic fungal infections. It is associated with many side effects which in some cases can be very severe and potentially lethal. Lipo-AB® is a true single bilayer liposomal drug delivery system, consisting of unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. Prior studies showed that the liposomal formulation of amphotericin B greatly reduces the side effects of the parent drug, such as nephrotoxicity. This study is designed to evaluate the safety and efficacy of Lipo-AB® in neutropenic patients with persistent fever in routine clinical practice in Taiwan. 1. Primary objective: • To evaluate the nephrotoxicity of Lipo-AB® (amphotericin B) treatment in neutropenic patients with persistent fever in Taiwan clinical practice. 2. Secondary objectives: (1) To evaluate the safety profile of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever in Taiwan clinical practice. (2) To evaluate the treatment efficacy of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever in Taiwan clinical practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Inorganic Nanoparticles: Tools to Emphasize the Janus Face of Amphotericin B.
Boudier A, Mammari N, Lamouroux E, Duval RE. · · 2023 · cited 1× · PMID 37887244 · DOI 10.3390/antibiotics12101543

Verify or expand the search:

Other TTY Biopharm trials

Trials by the same sponsor.

NCT06966284 — A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Pat · recruiting
NCT05359627 — A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency · Phase 1 · completed
NCT04070313 — A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan · Phase 2 · terminated
NCT03517618 — TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03511820 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TTY Biopharm
Last refreshed: 30 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03511820.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing